Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 6
Submit an article Journal homepage
374
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment

Ying C. OuBeiGene USA, Inc, San Mateo, CA, USA; Correspondence[email protected]
View further author information
,
Richard A. PrestonDepartment of Medicine, Division of Pharmacology, Miller School of Medicine, University of Miami, Coral Gables, FL, USA; View further author information
,
Thomas C. MarburyOrlando Clinical Research Center, Orlando, FL, USAView further author information
,
Zhiyu TangBeiGene USA, Inc, San Mateo, CA, USA; View further author information
,
William NovotnyBeiGene USA, Inc, San Mateo, CA, USA; View further author information
,
Manal TawashiBeiGene USA, Inc, San Mateo, CA, USA; View further author information
,
Ta-Kai LiBeiGene USA, Inc, San Mateo, CA, USA; View further author information
&
Srikumar SahasranamanBeiGene USA, Inc, San Mateo, CA, USA; View further author information
 show all
Pages 1355-1363 | Received 13 Dec 2019, Accepted 16 Jan 2020, Published online: 07 Feb 2020

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Yue Hu, Xiaojiao Li, Jingrui Liu, Hong Chen, Wenbo Zheng, Hong Zhang, Min Wu, Cuiyun Li, Xiaoxue Zhu, Jinfeng Lou, Pangke Yan, Nan Wu, Xiao Liu, Shiping Ma, Xu Wang, Yanhua Ding & Chengluan Xuan. (2022) Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment. Annals of Medicine 54:1, pages 2757-2768.
Read now
Constantine S. Tam, Ying C. Ou, Judith Trotman & Stephen Opat. (2021) Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib. Expert Review of Clinical Pharmacology 14:11, pages 1329-1344.
Read now
Praveen Ramakrishnan Geethakumari & Farrukh Awan. (2020) An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology 13:10, pages 1039-1046.
Read now

Articles from other publishers (8)

Chao Li, Lu Chen, Lixian Li & Wanyi Chen. (2023) Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models. European Journal of Pharmaceutical Sciences 189, pages 106564.
Crossref
Bilal Tariq, Stephanie Conto, Aileen Cohen, Srikumar Sahasranaman & Ying C. Ou. (2023) A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers. Clinical Pharmacology in Drug Development 12:8, pages 832-838.
Crossref
Lu Chen, Chao Li, Hao Bai, Lixian Li & Wanyi Chen. (2022) Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib. Frontiers in Pharmacology 13.
Crossref
Allison Rosenthal & Javier Munoz. (2022) Zanubrutinib for the Treatment of B-cell Malignancies. Oncology & Haematology 18:1, pages 44.
Crossref
Javier Muñoz, Yucai Wang, Preetesh Jain & Michael Wang. (2022) Zanubrutinib in lymphoproliferative disorders: a comprehensive review. Therapeutic Advances in Hematology 13, pages 204062072210939.
Crossref
Kun Wang, Xueting Yao, Miao Zhang, Dongyang Liu, Yuying Gao, Srikumar Sahasranaman & Ying C. Ou. (2021) Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator. CPT: Pharmacometrics & Systems Pharmacology 10:5, pages 441-454.
Crossref
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu & Christopher J. O’Donnell. (2021) Synthetic Approaches to the New Drugs Approved during 2019. Journal of Medicinal Chemistry 64:7, pages 3604-3657.
Crossref
Ying C. Ou, Lucy Liu, Bilal Tariq, Kun Wang, Ashutosh Jindal, Zhiyu Tang, Yuying Gao & Srikumar Sahasranaman. (2021) Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies. Clinical and Translational Science.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.